TREATMENT USE AND OVERALL SURVIVAL OF PATIENTS WITH UNRESECTABLE/METASTATIC MELANOMA IN COLOMBIA: A REAL WORLD STUDY

被引：0
|
作者：
Reyes, Sanchez J. M. [1 ]
Bolanos-Lopez, J. [2 ]
Bello, C. [2 ]
Rubio, A. C. [3 ]
Gonzalez, F. J. [2 ]
Toro, A. [2 ]
Chen, K. [4 ]
Arciniegas, J. [3 ]
Alarcon, B. A. [3 ]
Garcia, M. [1 ]
机构：
[1] Pfizer SAS, Bogota, Colombia
[2] Ctr Biociencias Sura, Medellin, Colombia
[3] Pfizer SAS, Bogota, Colombia
[4] Acaster Lloyd Consulting Ltd, Cambridge, MA USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
CO146
引用
收藏
页码：S44 / S44
页数：1
相关论文
共 50 条
  • [21] Dabrafenib in the treatment of metastatic or unresectable melanoma
    Khoja, Leila
    Hogg, David
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (03) : 265 - 276
  • [22] The Association of Radiation Jose-Fractionation and Immunotherapy Use With Overall Survival in Metastatic Melanoma Patients
    Wang, Shang-Jui
    Jhawar, Sachin R.
    Rivera-Nunez, Zorimar
    Silk, Ann W.
    Byun, John
    Miller, Eric
    Blakaj, Dukagjin
    Parikh, Rahul R.
    Weiner, Joseph
    Goyal, Sharad
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (06)
  • [23] Association of Radiation Dose-Fractionation and Immunotherapy Use with Overall Survival in Metastatic Melanoma Patients
    Wang, S. J.
    Jhawar, S. R.
    Rivera-Nunez, Z.
    Byun, J.
    Parikh, R. R.
    Weiner, J. P.
    Goyal, S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : S73 - S73
  • [24] EFFECTIVENESS AND SAFETY OF BRAF INHIBITORS IN THE TREATMENT OF BRAF-MUTATED UNRESECTABLE OR METASTATIC MELANOMA: REAL WORLD DATA
    Garcia-Avello, A.
    Vega-Coca, M. D.
    Abdel-Kader-Martin, L.
    Poyatos-Ruiz, L.
    Flores-Moreno, S.
    VALUE IN HEALTH, 2016, 19 (07) : A710 - A711
  • [25] Postdiagnosis aspirin use and overall survival in patients with melanoma
    Rachidi, Saleh
    Wallace, Kristin
    Li, Hong
    Lautenschlaeger, Tim
    Li, Zihai
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 78 (05) : 949 - +
  • [26] Real-World Trends in Treatment Use, Healthcare Costs, and Overall Survival Among Patients with Multiple Myeloma
    Fonseca, Rafael
    Abouzaid, Safiya
    Bonafede, Machaon
    Cai, Qian
    Parikh, Kejal
    Cosler, Leon
    Richardson, Paul
    BLOOD, 2016, 128 (22)
  • [27] Bone metastasis to predict treatment response rate and overall survival of patients with metastatic melanoma.
    Lee, Yesung
    Masub, Natasha
    Wechter, Todd
    Zhong, Judy
    Moran, Una
    Darvishian, Farbod
    Polsky, David
    Berman, Russell S.
    Shapiro, Richard L.
    Weber, Jeffrey S.
    Osman, Iman
    Pavlick, Anna C.
    Wilson, Melissa
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [28] REAL WORLD MANAGEMENT AND COSTS IN UNRESECTABLE METASTATIC MELANOMA (UM) PATIENTS TREATED AT THE ANTWERP UNIVERSITY HOSPITAL (UZA)
    Strens, D.
    Specenier, P.
    Peeters, M.
    VALUE IN HEALTH, 2014, 17 (07) : A627 - A627
  • [29] Real-world treatment patterns and overall survival in BRAF-mutant melanoma patients treated with immunotherapy or targeted therapy
    Atkins, Michael B.
    Julian, Cristina
    Secrest, Matthew H.
    Lee, Janet
    Abajo-Guijarro, Ana M.
    McKenna, Edward
    FUTURE ONCOLOGY, 2022, 18 (18) : 2233 - 2245
  • [30] IMPACT OF TREATMENT SEQUENCE ON OVERALL SURVIVAL IN METASTATIC PANCREATIC CANCER PATIENTS TREATED WITH LIPOSOMAL IRINOTECAN IN THE REAL-WORLD SETTING
    Kim, G. P.
    Surinach, A.
    Corvino, F. A.
    Cockrum, P.
    VALUE IN HEALTH, 2019, 22 : S58 - S58
12345